Developer docs
API playgroundTry for free, no card

Search company profiles

iLoF

Full company profile

uuid0000t5x

Namestring
iLoF
Legal namestring
iLoF
Websiteurl
ilof.tech
Company typeenum
Private
Founded yearint
2020
Descriptiontext

iLoF is a UK-headquartered digital health company founded in 2020 that operates an AI-powered, photonics-based platform for non-invasive patient screening and stratification in clinical trials. The core product is a cloud-based library of optical fingerprints — proprietary phenotypic signatures generated by shining light on microlitre-scale blood samples and applying AI to the resulting optical signals. The platform is described as label-free, target-agnostic, and capable of producing results in under 10 seconds without consumables, with published value claims of 40% cost savings and 70% time savings on patient screenings. Lead applications focus on Alzheimer's disease, with extensions into COVID-19 severity forecasting and Ovarian Cancer subtype stratification.

The business model is enterprise B2B, with iLoF selling screening and stratification services to global pharmaceutical, biotech, and clinical research organizations through a direct field sales motion. Pricing is quote-based and not publicly disclosed, and engagements are described as adapted to each clinical trial's protocol. The company operates three offices — London (HQ), New York (North America sales), and Porto (engineering/R&D) — with 11-50 employees. Notable partners include the Global Alzheimer's Platform Foundation, where iLoF contributes to the Bio-Hermes-002 observational study alongside Sanofi, Biogen, Eli Lilly, and Roche.

iLoF has raised approximately $10.5M in disclosed equity and grant funding across at least eight capital events from 2019 to 2025, including a $4.1M seed round led by Faber in July 2022 with M12 (Microsoft's venture fund) participating, a ~$2.68M European Innovation Council grant in 2023, and later strategic investments from Hamamatsu Ventures and Lince Capital. The leadership team comprises three co-founders (Luis Valente, CEO; Mehak Mumtaz, COO; Paula Sampaio, CSO) supported by advisors with senior executive experience at Microsoft, Google, Disney, and Amazon, plus photonics and digital health regulatory expertise. Public recognition includes CB Insights' most promising Digital Health companies list and Financial Times' Transformational Business in Healthcare designation.

Short descriptiontext

iLoF is a UK-based digital health company (founded 2020) operating an AI-powered photonics platform that generates optical fingerprints from blood samples to non-invasively stratify patients for pharmaceutical and biotech clinical trials.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI drug discovery, patient stratification platform, clinical trial screening, optical biomarker analysis, photonics biosensing
Industry3 codes
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAA
High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
NAICS code1 code
  • Medical Laboratories621511
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
Product category
AI-powered digital health drug discovery platform
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Screening and Stratification Services
TypeSubscription Recurring
Description

iLoF provides a blood-based screening test that stratifies patients for clinical trials, offering pharmaceutical and biotech clients patient screening services. The platform is adapted to each clinical trial's needs, suggesting a subscription or service-based model with per-test or per-screening pricing.

ilof.tech
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

iLoF provides an AI-powered cloud platform that combines photonics and machine learning to convert small biological samples into optical fingerprints used as phenotypic signatures. Its blood-based screening test stratifies patients for clinical trials, removing heterogeneity due to underlying pathophysiology, disease stage or progression. Services are adapted to each clinical trial's needs and target pharmaceutical, biotech, and clinical research customers worldwide.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 40% cost savings on patient screenings
+3 more records
Product overview1 text field

iLoF offers a unified platform architecture centered on its AI-powered iLoF Platform, which comprises a cloud-based library of optical fingerprints combined with the iLoF Method for blood-based patient screening. The platform integrates photonics and AI to collect optical signals that convert biological samples into phenotypic signatures, enabling non-invasive tracking, screening, and stratification for personalized drug discovery and clinical trial optimization.

Product and service2 records
1iLoF Platform
CategoryAI drug discovery platform
Description

A cloud-based library of optical fingerprints powered by photonics and AI that provides non-invasive tracking, screening and stratification of patients in drug discovery, adapted to each clinical trial's needs. Used by pharmaceutical, biotech and clinical research organizations.

2iLoF Method
CategoryClinical trial screening service
Description

A blood-based screening test that stratifies patients for clinical trials, removing heterogeneity due to underlying pathophysiology, disease stage or degree of progression. Requires only microlitres of blood and produces results in under 10 seconds without consumables. Delivered to pharmaceutical, biotech and clinical research customers.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-07-01
Description

iLoF raised $4.1 million in seed funding in July 2022 with the explicit aim of accelerating collaborations with global pharmaceutical, biotech, and clinical firms to enhance personalized drug discovery using AI technology. These collaborations involve using iLoF's platform for patient screening and stratification in clinical trials.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

iLoF is listed as a contributing partner in the Global Alzheimer's Platform Foundation's Bio-Hermes-002 observational study, which evaluates blood-based and digital biomarkers alongside imaging to improve prediction, detection, and diagnosis of Alzheimer's disease. GAP's Bio-Hermes-002 study involves pharmaceutical partners including Sanofi, Biogen, Eli Lilly, Roche, and others, with data stored on the AD Workbench platform from the Gates Ventures Alzheimer's Disease Data Initiative.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Tempus AI
TypeBroad incumbent
Description

Tempus is a large AI-driven precision medicine platform that combines molecular data, clinical data, and AI to support pharma R&D, clinical trial design, and patient stratification. It overlaps with iLoF on the AI-for-clinical-trial-stratification use case, though its data modality (multi-omics) and scale are much broader than iLoF's photonic-optical fingerprint approach.

TypeDirect peer
Description

Owkin is an AI biotech that builds patient stratification and outcome-prediction models from multimodal patient data for pharma clinical trials. Like iLoF, it sells AI tools to pharma and biotech to improve trial design and drug development, with comparable GTM and customer base.

TypeBroad incumbent
Description

SOPHiA Genetics offers an AI-powered platform that analyzes complex genomic and multimodal patient data to support cancer and rare disease clinical research. It serves pharma and clinical research customers with data-driven patient insights, overlapping iLoF's clinical trial stratification mission but using sequencing rather than photonic-optical data.

TypeBroad incumbent
Description

Exscientia is an AI-driven pharma company that combines AI drug design with patient-derived data to prioritize and design clinical candidates. It shares iLoF's pharma-focused AI-for-drug-discovery positioning, though its emphasis is on compound design rather than blood-based screening for trial stratification.

TypeBroad incumbent
Description

Recursion combines high-throughput wet-lab experimentation with AI-driven phenotypic screening to discover and develop new therapeutics. It overlaps with iLoF in the AI-enabled phenotypic screening space, but operates at a much larger scale with proprietary lab automation rather than photonic-optical fingerprinting.

TypeBroad incumbent
Description

Schrödinger provides a physics-based computational platform for molecular simulation and drug discovery, sold to pharma and biotech. It addresses a related but distinct step in the pharma R&D workflow versus iLoF's trial stratification focus, but shares the AI/ML-for-pharma enterprise GTM motion.

TypeDirect peer
Description

CytoReason is an AI company that builds computational disease models from multi-omics and clinical data to support pharma drug development and trial stratification. Like iLoF, it sells AI-driven patient insights to pharma R&D teams and competes for similar enterprise budgets.

8Aignostics
TypeEmerging player
Description

Aignostics applies AI to pathology and multi-modal patient data to support pharma biomarker discovery and clinical trial patient selection. It overlaps with iLoF's clinical trial stratification mission but uses histology/pathology rather than photonic-optical signals.

TypeEmerging player
Description

Lantern Pharma uses AI and genomic data to identify responders and guide precision oncology drug development. It shares iLoF's AI-enabled patient stratification thesis in oncology but is more vertically integrated into drug development.

TypeEmerging player
Description

C2i Genomics provides AI-driven liquid-biopsy-based minimal residual disease (MRD) detection to support cancer clinical trials and treatment monitoring. Like iLoF, it uses blood-based biomarkers with AI to support pharma clinical trials, but focuses specifically on oncology MRD rather than multi-disease stratification.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds12 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors17 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

iLoF

AI-powered digital health drug discovery platformilof.tech

iLoF is a UK-based digital health company (founded 2020) operating an AI-powered photonics platform that generates optical fingerprints from blood samples to non-invasively stratify patients for pharmaceutical and biotech clinical trials.

What iLoF does

iLoF is a UK-headquartered digital health company founded in 2020 that operates an AI-powered, photonics-based platform for non-invasive patient screening and stratification in clinical trials. The core product is a cloud-based library of optical fingerprints — proprietary phenotypic signatures generated by shining light on microlitre-scale blood samples and applying AI to the resulting optical signals. The platform is described as label-free, target-agnostic, and capable of producing results in under 10 seconds without consumables, with published value claims of 40% cost savings and 70% time savings on patient screenings. Lead applications focus on Alzheimer's disease, with extensions into COVID-19 severity forecasting and Ovarian Cancer subtype stratification.

The business model is enterprise B2B, with iLoF selling screening and stratification services to global pharmaceutical, biotech, and clinical research organizations through a direct field sales motion. Pricing is quote-based and not publicly disclosed, and engagements are described as adapted to each clinical trial's protocol. The company operates three offices — London (HQ), New York (North America sales), and Porto (engineering/R&D) — with 11-50 employees. Notable partners include the Global Alzheimer's Platform Foundation, where iLoF contributes to the Bio-Hermes-002 observational study alongside Sanofi, Biogen, Eli Lilly, and Roche.

iLoF has raised approximately $10.5M in disclosed equity and grant funding across at least eight capital events from 2019 to 2025, including a $4.1M seed round led by Faber in July 2022 with M12 (Microsoft's venture fund) participating, a ~$2.68M European Innovation Council grant in 2023, and later strategic investments from Hamamatsu Ventures and Lince Capital. The leadership team comprises three co-founders (Luis Valente, CEO; Mehak Mumtaz, COO; Paula Sampaio, CSO) supported by advisors with senior executive experience at Microsoft, Google, Disney, and Amazon, plus photonics and digital health regulatory expertise. Public recognition includes CB Insights' most promising Digital Health companies list and Financial Times' Transformational Business in Healthcare designation.

iLoF firmographics

Firmographics
Name
iLoF
Legal name
iLoF
Website
https://ilof.tech
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Short description
iLoF is a UK-based digital health company (founded 2020) operating an AI-powered photonics platform that generates optical fingerprints from blood samples to non-invasively stratify patients for pharmaceutical and biotech clinical trials.
Ownership category
akta.pro rank

iLoF industry classification

Industry
Product category
AI-powered digital health drug discovery platform
NAICS
Medical Laboratories (621511)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAA
High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)

Keywords

  • AI drug discovery
  • Patient stratification platform
  • Clinical trial screening
  • Optical biomarker analysis
  • Photonics biosensing

Where iLoF is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices3 records

Markets served

iLoF business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Screening and Stratification Services: iLoF provides a blood-based screening test that stratifies patients for clinical trials, offering pharmaceutical and biotech clients patient screening services. The platform is adapted to each clinical trial's needs, suggesting a subscription or service-based model with per-test or per-screening pricing.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

iLoF product offering

Product offering

Core offering

iLoF provides an AI-powered cloud platform that combines photonics and machine learning to convert small biological samples into optical fingerprints used as phenotypic signatures. Its blood-based screening test stratifies patients for clinical trials, removing heterogeneity due to underlying pathophysiology, disease stage or progression. Services are adapted to each clinical trial's needs and target pharmaceutical, biotech, and clinical research customers worldwide.

Product overview

iLoF offers a unified platform architecture centered on its AI-powered iLoF Platform, which comprises a cloud-based library of optical fingerprints combined with the iLoF Method for blood-based patient screening. The platform integrates photonics and AI to collect optical signals that convert biological samples into phenotypic signatures, enabling non-invasive tracking, screening, and stratification for personalized drug discovery and clinical trial optimization.

Differentiator

Problem solved

Functional benefit

Products and services

  • iLoF Platform A cloud-based library of optical fingerprints powered by photonics and AI that provides non-invasive tracking, screening and stratification of patients in drug discovery, adapted to each clinical trial's needs. Used by pharmaceutical, biotech and clinical research organizations.
  • iLoF Method A blood-based screening test that stratifies patients for clinical trials, removing heterogeneity due to underlying pathophysiology, disease stage or degree of progression. Requires only microlitres of blood and produces results in under 10 seconds without consumables. Delivered to pharmaceutical, biotech and clinical research customers.

Quantifiable outcome

  • 40% cost savings on patient screenings
  • +3 more outcomes

Companies that use iLoF

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles3 records

iLoF technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

iLoF partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Global pharmaceutical, biotech, and clinical firms (unnamed collaborations)coreStrategic or Co-development Partner · 1 July 2022iLoF raised $4.1 million in seed funding in July 2022 with the explicit aim of accelerating collaborations with global pharmaceutical, biotech, and clinical firms to enhance personalized drug discovery using AI technology. These collaborations involve using iLoF's platform for patient screening and stratification in clinical trials.
  • Global Alzheimer's Platform Foundation (GAP)coreStrategic or Co-development PartneriLoF is listed as a contributing partner in the Global Alzheimer's Platform Foundation's Bio-Hermes-002 observational study, which evaluates blood-based and digital biomarkers alongside imaging to improve prediction, detection, and diagnosis of Alzheimer's disease. GAP's Bio-Hermes-002 study involves pharmaceutical partners including Sanofi, Biogen, Eli Lilly, Roche, and others, with data stored on the AD Workbench platform from the Gates Ventures Alzheimer's Disease Data Initiative.

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

iLoF competitors and assessment

Company assessment

Broad incumbents

  • Tempus AI: Tempus is a large AI-driven precision medicine platform that combines molecular data, clinical data, and AI to support pharma R&D, clinical trial design, and patient stratification. It overlaps with iLoF on the AI-for-clinical-trial-stratification use case, though its data modality (multi-omics) and scale are much broader than iLoF's photonic-optical fingerprint approach.
  • SOPHiA Genetics: SOPHiA Genetics offers an AI-powered platform that analyzes complex genomic and multimodal patient data to support cancer and rare disease clinical research. It serves pharma and clinical research customers with data-driven patient insights, overlapping iLoF's clinical trial stratification mission but using sequencing rather than photonic-optical data.
  • Exscientia: Exscientia is an AI-driven pharma company that combines AI drug design with patient-derived data to prioritize and design clinical candidates. It shares iLoF's pharma-focused AI-for-drug-discovery positioning, though its emphasis is on compound design rather than blood-based screening for trial stratification.
  • Recursion Pharmaceuticals: Recursion combines high-throughput wet-lab experimentation with AI-driven phenotypic screening to discover and develop new therapeutics. It overlaps with iLoF in the AI-enabled phenotypic screening space, but operates at a much larger scale with proprietary lab automation rather than photonic-optical fingerprinting.
  • Schrödinger: Schrödinger provides a physics-based computational platform for molecular simulation and drug discovery, sold to pharma and biotech. It addresses a related but distinct step in the pharma R&D workflow versus iLoF's trial stratification focus, but shares the AI/ML-for-pharma enterprise GTM motion.

Direct peers

  • Owkin: Owkin is an AI biotech that builds patient stratification and outcome-prediction models from multimodal patient data for pharma clinical trials. Like iLoF, it sells AI tools to pharma and biotech to improve trial design and drug development, with comparable GTM and customer base.
  • CytoReason: CytoReason is an AI company that builds computational disease models from multi-omics and clinical data to support pharma drug development and trial stratification. Like iLoF, it sells AI-driven patient insights to pharma R&D teams and competes for similar enterprise budgets.

Emerging players

  • Aignostics: Aignostics applies AI to pathology and multi-modal patient data to support pharma biomarker discovery and clinical trial patient selection. It overlaps with iLoF's clinical trial stratification mission but uses histology/pathology rather than photonic-optical signals.
  • Lantern Pharma: Lantern Pharma uses AI and genomic data to identify responders and guide precision oncology drug development. It shares iLoF's AI-enabled patient stratification thesis in oncology but is more vertically integrated into drug development.
  • C2i Genomics: C2i Genomics provides AI-driven liquid-biopsy-based minimal residual disease (MRD) detection to support cancer clinical trials and treatment monitoring. Like iLoF, it uses blood-based biomarkers with AI to support pharma clinical trials, but focuses specifically on oncology MRD rather than multi-disease stratification.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key highlights7 records

Customer concentration

iLoF social profiles

Digital presence

iLoF financial estimates

Financial estimate

Revenue estimate

Valuation estimate

iLoF leadership team

Management profile

Number of profiles

Profiles8 records

iLoF funding detail

Funding detail

Funding overview

Funding rounds12 records

Investors17 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

iLoF M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about iLoF

What does iLoF do?

iLoF provides an AI-powered cloud platform that combines photonics and machine learning to convert small biological samples into optical fingerprints used as phenotypic signatures. Its blood-based screening test stratifies patients for clinical trials, removing heterogeneity due to underlying pathophysiology, disease stage or progression. Services are adapted to each clinical trial's needs and target pharmaceutical, biotech, and clinical research customers worldwide.

Is iLoF a public or private company?

iLoF is a private company. It is classified as venture growth investor backed and is currently operating.

When was iLoF founded?

iLoF was founded in 2020. It employs 11 to 50 people.

Where is iLoF based?

iLoF is headquartered in London, United Kingdom, in the Europe region.

How does iLoF make money?

One revenue line is on record: screening and Stratification Services.

Who are iLoF's main competitors?

Broad incumbents on record are Tempus AI, SOPHiA Genetics, Exscientia, Recursion Pharmaceuticals and Schrödinger. Direct peers are Owkin and CytoReason. Emerging players are Aignostics, Lantern Pharma and C2i Genomics.

Does iLoF have an API?

No public API is recorded for iLoF.

What industry is iLoF in?

iLoF's product category is AI-powered digital health drug discovery platform. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening), with a secondary code of HLAAAIAA, High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening). Its NAICS code is 621511 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Nate아이로프, KES 2026서 빛으로 읽는 혈액 진단 '옵토믹스' 선보여…"한 번의 채혈로 여러 질병 가능성을 가려낸다" : 네이트 뉴스iLOF showcased its Optomics platform at KES 2026, using AI and photonics to analyze blood samples in 30 seconds without chemical labels. The platform achieved a 0.99 cross-validation metric in lung cancer research and 95% sensitivity in an independent cohort. The company plans to expand in the US and Europe, including a CLIA lab in the US.PR NewswireiLoF and Industry Leader Bluepharma Announce Strategic Collaboration to Deploy AI-Powered Optomics® for Faster Drug Development and to Advance the Future of Personalised MedicineiLoF and Bluepharma announced a strategic collaboration to integrate iLoF's AI-powered Optomics® photonics platform across Bluepharma's pharmaceutical value chain, spanning drug development, R&D, and manufacturing. The partnership will deploy Optomics® in real-world settings to evaluate the platform against regulatory and quality standards, while advancing personalized medicine capabilities. This collaboration builds on iLoF's recent commercial momentum, including a $1.5M clinical research contract for Alzheimer's disease study sites in the US, Canada, and UK.InvestorshangoutStrategic Health Partnership: iLoF and Hamamatsu UniteiLoF and Hamamatsu announced a strategic partnership to advance personalized medicine through iLoF's AI-powered Optomics platform. The collaboration aims to expand iLoF's presence in Asian markets, including Japan, and supports a recent clinical research contract for Alzheimer's diagnostics.PR NewswireiLoF and Industry Leader Hamamatsu Announce Strategic Investment in a Collaboration to Advance the Future of Personalized MedicineHamamatsu Ventures invested in iLoF to accelerate its Optomics AI photonics platform for personalized medicine. The collaboration aims to expand in US and Japanese markets and develop new AI methodologies. iLoF also secured a $1.5M clinical research contract for a global Alzheimer's study.RbjDigital health startup iLoF leverages AI and photonics platform to accelerate personalized drug developmentiLoF, a UK digital health startup, uses AI and photonics to screen clinical trial participants via blood tests, cutting screening time by up to 70% and costs by 40%. The company is expanding into Rochester, NY, and participating in Luminate NY's accelerator program, which offers $100,000 in initial investment.TmcnetiLoF Secures $1.5M Clinical Research Contract to Deploy its Optomics® Platform in Leading International Alzheimer's Study and Expands into the USiLoF secured a £1.2M (~$1.5M) clinical research contract from Innovate UK to deploy its Optomics platform in the Bio-Hermes-002 Alzheimer's study. The study, led by GAP, will evaluate over 1,000 participants across the US, Canada, and UK. iLoF's US operation will be supported by Luminate.PR NewswireiLoF Secures $1.5M Clinical Research Contract to Deploy its Optomics® Platform in Leading International Alzheimer's Study and Expands into the USiLoF secured a £1.2M (~$1.5M) clinical research contract from Innovate UK to deploy its Optomics platform in the Bio-Hermes-002 Alzheimer's study. The transnational study, led by GAP, will evaluate technologies with over 1,000 participants across the US, Canada, and UK. iLoF's US operation will be supported by Luminate.Business InsiderThese 3 founders are using AI to analyze patients' biological profiles and recommend drugs. Here's the 15-slide pitch deck they used to raise $5 million backed by Microsoft.iLoF, a drug discovery startup based in Oxford and Porto, raised $5 million in seed funding from Faber and Microsoft's M12. The company uses AI to match patients to medications based on genetic profiles and enables biotech and pharma firms to access this data for clinical trials.The SaaS NewsiLoF Raises $4.1 Million in Seed RoundOxford-based digital health company iLoF raised $4.1 million in a seed funding round led by Fab, with participation from M12 and other investors. The company has secured a total of $8 million to date and will use the funds to accelerate engagements with global pharmaceutical and biotech corporations for clinical pilots.